SCN9A rs121918667: Understanding Paroxysmal Extreme Pain Disorder
The rs121918667 variant is a specific genetic change within the SCN9A gene that has been identified in individuals with paroxysmal extreme pain disorder (PEPD). This condition is characterized by intense, episodic pain and is linked to gain-of-function changes in the body's sodium channel signaling.
What each genotype means
Typical SCN9A genotype
This genotype represents the common, non-variant form of the SCN9A gene at this location. It is not associated with the rare, gain-of-function mutations linked to paroxysmal extreme pain disorder.
This is the most common genotype found in the general population across all ancestries.
Potential carrier status
This genotype indicates the presence of one copy of a variant that has been studied in the context of hereditary pain syndromes. Because paroxysmal extreme pain disorder is typically inherited in an autosomal dominant manner, you should discuss the clinical significance of this specific variant with a genetic counselor or physician to understand if it is relevant to your health.
This genotype is extremely rare in the general population.
Rare variant genotype
This genotype indicates the presence of two copies of a rare variant in the SCN9A gene. Research into SCN9A variants often focuses on their potential to cause gain-of-function effects in sodium channels, which can lead to pain disorders; please consult with a medical professional to interpret this result in the context of your personal and family health history.
This genotype is exceptionally rare and is not typically observed in the general population.
What is the rs121918667 Variant?
The rs121918667 variant is a specific alteration located within the SCN9A gene, which provides the blueprint for the NaV1.7 sodium channel. In genetics, a variant like this represents a change in the DNA sequence compared to the reference genome. Because SCN9A is critical for how our nervous system processes pain, even small changes in its sequence can have significant functional consequences. This particular variant is categorized as a pathogenic variant in clinical databases, meaning it is strongly associated with specific hereditary pain syndromes. It is important to note that genetic variants are not inherently 'good' or 'bad' in a moral sense; rather, they are biological markers that can influence how our proteins function. When this variant is present, it can alter the behavior of the sodium channels in nerve cells, potentially leading to the clinical symptoms observed in affected individuals.
The Role of the SCN9A Gene
The SCN9A gene is responsible for producing the alpha subunit of the NaV1.7 voltage-gated sodium channel. These channels act like tiny gates on the surface of sensory neurons, controlling the flow of sodium ions into the cell. This flow of ions is essential for generating electrical signals that travel along nerves to transmit information about pain and touch to the brain. When the SCN9A gene functions normally, these channels open and close in a precise, regulated manner. However, variants in this gene can disrupt this process. In the case of conditions like paroxysmal extreme pain disorder, the variant causes the channels to remain open longer than they should, or to open too easily. This leads to an over-excitation of the nerve cells, which the brain interprets as intense, often debilitating, episodes of pain.
Research and Clinical Associations
Scientific research has established a clear link between specific SCN9A variants and a spectrum of neuropathic pain disorders, including paroxysmal extreme pain disorder (PEPD), erythromelalgia, and small fiber neuropathy. PEPD is an extremely rare, autosomal dominant condition. Studies have shown that the variants associated with PEPD typically result in a 'gain-of-function' effect, where the sodium channels fail to inactivate properly, leading to persistent sodium currents. Evidence for these associations is considered moderate to strong in clinical genetics, as these variants have been identified in families with clear histories of these pain syndromes. While the molecular mechanism is well-documented in laboratory settings, the clinical presentation can vary between individuals. Researchers continue to study these variants to better understand how they influence the severity of pain and how they might respond to specific pharmacological interventions, such as sodium channel blockers.
Population Frequency and Interpretation
The rs121918667 variant is classified as rare in the general population. Because it is associated with a specific, rare medical condition, it is not commonly found in large-scale, healthy population databases. When a variant is this rare, it is often identified through clinical testing of individuals who are already experiencing symptoms, rather than through general population screening. It is important to understand that having a rare variant does not automatically mean an individual will experience the full spectrum of symptoms associated with a condition. Genetic penetrance—the proportion of people with a variant who actually show symptoms—can be influenced by other genetic factors and environmental triggers. If you have received information about this variant from a genetic test, it is essential to discuss the findings with a qualified healthcare provider or a genetic counselor who can interpret the results in the context of your personal and family medical history.
Navigating Genetic Information
Understanding your genetic information is a personal journey, but it should always be done in partnership with medical professionals. If you have been identified as a carrier of a variant in the SCN9A gene, you cannot use this information to self-diagnose or predict your future health with certainty. Genetic testing results are complex and require professional interpretation to understand their clinical significance. Furthermore, if you are managing a pain condition, never make changes to your medication or treatment plan based on genetic reports without consulting your clinician or pharmacist. They are the only ones who can safely integrate your genetic data with your clinical symptoms to provide appropriate care. Genetic information is a tool for health management, not a substitute for professional medical advice, diagnosis, or treatment.
How common is this variant?
The rs121918667 variant is considered rare in the general population, with limited data available across diverse ancestral groups.
Frequently asked questions
What is paroxysmal extreme pain disorder?
Paroxysmal extreme pain disorder is a rare, inherited condition characterized by episodes of intense, burning pain, often accompanied by skin flushing. It is caused by specific variants in the SCN9A gene that affect how nerve cells signal pain.
Can I be tested for SCN9A variants?
Yes, molecular genetic testing can identify variants in the SCN9A gene. This is typically performed in a clinical setting for individuals who exhibit symptoms of neuropathic pain syndromes.
Is there a cure for SCN9A-related pain?
While there is no cure for the underlying genetic condition, certain medications, such as carbamazepine, have been shown to be effective in managing symptoms for some patients. Always consult a doctor for treatment options.
What should I do if I have this variant?
If you have been identified as having this variant, you should discuss the results with a genetic counselor or your primary care physician. They can help you understand what this means for your health and whether any clinical follow-up is necessary.
Sources & further reading
Educational information only, last refreshed 9/21/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121918667?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in SCN9A
This voltage-gated sodium channel variant modulates nociceptive sensitivity, causing carriers to exhibit higher pain thresholds across various sensory modalities.
This variant in the SCN9A gene is associated with autosomal dominant painful channelopathies, including primary erythromelalgia.